GeneLink BioSciences, Inc. Ranked Number 92 Fastest Growing Company in North America on Deloitte's 2009 Technology Fast 500TM

Attributes its 1,991% Revenue Growth to Launch of GeneWize Life Sciences, Inc.

• Press Release
• Source: GeneLink BioSciences, Inc.
• On 9:01 am EDT, Wednesday October 21, 2009

ORLANDO, Fla.--(BUSINESS WIRE)--GeneLink BioSciences, Inc. (OTCBB: GNLK.OB, “the Company,” or “GeneLink”), today announced that it ranked number 92 on Technology Fast 500^TM, Deloitte LLP’s ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year growth during the five year period from 2004-2008. GeneLink experienced 1,991 percent growth during this period.

Related Quotes

Symbol	Price	Change
GNLK.OB	0.16	+0.01

{"s" : "gnlk.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

“Being named to the Deloitte 500 is an outstanding achievement”, said Monte Taylor, GeneLink CEO. “Substantially all of GeneLink’s revenue commenced with the launch of GeneWize Life Sciences, Inc. in the third quarter of 2008 and was based on roughly a half a year of revenue producing operations. Revenue for 2009 has already exceeded fiscal year 2008 and, assuming current trends at GeneWize continue, 2010 revenue should be even greater. As we continue to expand our science, product offerings, and the scope of our marketing efforts, we look forward to future growth.”

“Technology Fast 500^TM recognizes innovative companies that have broken down barriers to success and defied the odds with their remarkable five-year revenue growth,” said Phil Asmundson, Vice Chairman and U.S. Technology, Media and Telecommunications leader, Deloitte LLP. “We congratulate GeneLink BioSciences, Inc. on this accomplishment.”

“With its impressive five-year growth, GeneLink BioSciences, Inc. has earned its position among the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America,” said Mark Jensen, Managing Partner, Technology and Venture Capital Services, Deloitte & Touche LLP. “Deloitte is proud to honor GeneLink for its achievement.”

Technology Fast 500^TM Selection and Qualifying Criteria

Technology Fast 500^TM provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. This ranking is compiled from nominations submitted directly to the Technology Fast 500^TM website, and public company database research conducted by Deloitte. Technology Fast 500^TM award winners for 2009 are selected based on percentage fiscal year revenue growth during the five year period from 2004 to 2008.

In order to be eligible for Technology Fast 500^TM recognition, companies must own proprietary intellectual property or proprietary technology that contributes to a significant portion of the company’s operating revenues. Using other companies’ technology or intellectual property in a unique way does not satisfy this requirement. Consulting companies, professional service firms, etc. are not eligible unless they have proprietary technology that contributes to a significant portion of their operating revenues.

Technology Fast 500^TM eligibility requirements also include base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. These revenues must have more than doubled between 2004 and 2008. Additionally companies must be in business for a minimum of five years, and be headquartered in North America. See www.deloitte.com/us/about for additional information.

About GeneLink BioSciences, Inc:

GeneLink is a leading biosciences company specializing in consumer genomics. GeneLink’s patented and patent pending technologies include proprietary genetic assessments linked to personalized health, beauty and wellness applications. Its DNA assessments provide information that enables the customization of nutritional products, skincare products and health maintenance regimens designed to fulfill individual consumer needs. For more information visit www.genelinkbio.com

About GeneWize Life Sciences, Inc.:

GeneWize is the first direct selling industry company to focus on providing individually customized nutritional and skin care formulations based on a consumer’s personal DNA assessment. The company’s mission is to empower individuals to take personal responsibility and control of their health.

Every LifeMap Me™ custom nutritional formula and LifeMap Me™ custom skin care formula is “made exclusively” for each customer. This is a revolutionary new scientific approach to delivering products that truly address individual needs. GeneWize is committed to innovating and manufacturing the highest quality, scientifically proven health, beauty and wellness products. For more information on GeneWize, please visit: www.genewize.com

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

GeneLink/GeneWize
Monte Taylor, CEO, 800-558-4363
mtaylor@genelinkbio.com
or
GeneLink Investor Relations:
407-772-7164
IR@genelinkbio.com